NovaBay Pharmaceuticals (NBY) Names Dr. Mark Andersone as Chief Scientific Officer
NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY) has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company.
Dr. Anderson's credentials include over 17 years of successfully leading research and development programs. He holds numerous patents, patent applications and publications to his credit. Prior to joining NovaBay, he has held senior positions at Myriad Genetics, Elitra Pharmaceuticals, Pfizer-Agouron and Ligand-Glycomed. Dr. Anderson holds a doctorate from Purdue University, and completed postdoctoral studies in chemical biology at Harvard University.
[SM]
Dr. Anderson's credentials include over 17 years of successfully leading research and development programs. He holds numerous patents, patent applications and publications to his credit. Prior to joining NovaBay, he has held senior positions at Myriad Genetics, Elitra Pharmaceuticals, Pfizer-Agouron and Ligand-Glycomed. Dr. Anderson holds a doctorate from Purdue University, and completed postdoctoral studies in chemical biology at Harvard University.
[SM]
You May Also Be Interested In
- McDonald's (MCD) Promotes Dave Hoffmann to President of APMEA
- Art's Way Manufacturing (ARTW) Appoints New Sales, Marketing Director
- QLT Inc. (QLTI) Issues Response to Nordic Biotech Notification on Board Nominees
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
